Sponsored By:

New Breakout Target for Top Biotech Amgen

AMGN broke from a small triangle on encouraging results for a new oncology drug

   

Amgen (NASDAQ:AMGN) — This biotech company has been a leader in the development of genetically based research and treatment for cancer, anemia, rheumatoid arthritis and a host of other major illnesses. It markets five of the world’s best-selling biotech drugs. S&P estimates 2013 earnings per share (EPS) at $7.21 and recently added a 2014 estimate of $8.

We’ve followed AMGN in the Trade of the Day for over a year, recommending it at various lower prices. The last time was on Feb. 27, when it was suggested as a buy under $90.

On Thursday, Amgen presented encouraging results for a new oncology drug for treatment of melanoma, the most aggressive form of skin cancer. This announcement brought in late-afternoon buyers and broke the stock from a small triangle with a top at $94. Support is now at $92.

Buy under $95 for a trading target of $115. AMGN is also recommended for inclusion in a long-term portfolio as a cornerstone biotechnology stock.

03 22 13 amgn 300x199 New Breakout Target for Top Biotech Amgen
Click to Enlarge

chart key 300x84 New Breakout Target for Top Biotech Amgen


Article printed from InvestorPlace Media, http://investorplace.com/2013/03/trade-of-the-day-amgen-nasdaq-amgn-7/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.